<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
  </style>
</head>
<body>
  <h1>OMGs / MDT Report</h1>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-17_20-12-16</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Heavily pretreated recurrent metastatic ovarian cancer with severe anemia and incomplete pathology/imaging/biomarker data; prognosis guarded and decisions must follow stabilization and clarified goals.

Core Treatment Strategy:
- Urgently correct severe anemia and optimize nutrition/organ function before any further anti-tumor treatment [@20250624|14501112; @20250624|14000385].  
- After stabilization, reassess ECOG, symptoms, and patient preferences; prioritize symptom-led palliative/supportive care if performance status poor.  
- Retrieve full primary pathology and any prior molecular reports; if absent, evaluate feasibility/value of new profiling (including BRCA/HRD).  
- Obtain complete 2025-04-09 CT report (±PET/CT if justified) to define burden/complications and identify candidates for local palliation.  

Change Triggers:
- If performance status remains ≥3 or patient declines further therapy, shift fully to best supportive and hospice-oriented care.  
- If performance status ≤2 and patient desires treatment, reconsider limited systemic options versus focused local interventions at repeat MDT review.</pre>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>2019.3.26 因卵巢癌外院手术，术后二次热灌注，多西+顺铂，化疗六次，多西+卡铂，2019.8 结束治疗PRR2019.10 血CA125升高，110左右，2019.11 挽救化疗 多柔比星脂质体3次因疫情停止治疗2021.5 再次肿瘤复发，白紫+贝伐化疗 六次，贝伐维持 2022.062022.7 多柔比星单药治疗 5次2023.1 口服安罗+尼拉2024.9 因肠梗阻停药2024.9 手术，肠造瘘，再次化疗，多柔比星+奈达铂化疗 3次，后联合免疫治疗，一次，SD，换药2025.4.9 外院CT： 卵巢癌多发转移东院肿瘤标志物（2025.06.25）：CA19-9:23.40U/ml,CA125:651.00U/ml↑,CA15-3:156.00U/ml↑,AFP:1.04ng/ml,CEA:1.13ng/ml,HE4:1210.00pmol/L↑,ROMA:99.50%(绝经前)↑,ROMA.:98.26%(绝经后)↑。东院生化检测（2025.06.24）：TBIL:3.6umol/l,DBIL:1.7umol/l,IBIL:1.9umol/L,ALP:143.6U/L↑,ALT:8.6U/l,AST:18.0U/L,ASTM:6.9U/L,LDH:209U/L,GGT:35U/L,TP:70.5g/l,ALB:39.5g/l↓,GELO:31.0g/l,A/G:1.27,NEFA:0.30mmol/L,PA:172mg/L↓,GLDH:3.8U/L,UREA:11.22mmol/l↑,CRE:93umol/l↑,UA:362umol/l↑。东院XN9000（2025.06.24）：WBC:7.8*10^9/L,LYM:18.2%↓,MID:6.2%,GRAN:74.1%,EOS:1.20%,BASO:0.30%,LYM#:1.4*10^9/L,MID#:0.5*10^9/L,GRAN#:5.8*10^9/L,EOS#:0.09*10^9/L,BASO#:0.02*10^9/L,RBC:2.41*10^12/L↓,HGB:67g/l↓,HCT:22.3%↓,MCV:92.5fl,MCH:27.8pg,MCHC:300.0g/l↓,RDWCV:16.1%↑,RDWSD:56↑,PLT:198*10^9/L,MPV:8.4fl,PCT:0.17%,PDW:7%↓,NL:4.14。</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6 cycles&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;多西+顺铂&quot;,&quot;多西+卡铂&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;1.04 ng/ml&quot;,&quot;CA125&quot;:&quot;651.00 U/ml&quot;,&quot;CA15-3&quot;:&quot;156.00 U/ml&quot;,&quot;CA19-9&quot;:&quot;23.40 U/ml&quot;,&quot;CEA&quot;:&quot;1.13 ng/ml&quot;,&quot;HE4&quot;:&quot;1210.00 pmol/L&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;ROMA&quot;:&quot;99.50% (premenopausal); 98.26% (postmenopausal)&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;Ovarian cancer with multiple metastases (CT 2025-04-09)&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[],&quot;histology&quot;:&quot;Unknown&quot;,&quot;laterality&quot;:&quot;Unknown&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;HRD&quot;:&quot;Unknown&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;cycles&quot;:&quot;6 cycles&quot;,&quot;end_date&quot;:&quot;2019-08&quot;,&quot;intent&quot;:&quot;Adjuvant&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;regimen&quot;:&quot;多西+顺铂; 多西+卡铂&quot;,&quot;start_date&quot;:&quot;2019-03-26&quot;},{&quot;cycles&quot;:&quot;3 cycles&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;多柔比星脂质体&quot;,&quot;start_date&quot;:&quot;2019-11&quot;},{&quot;cycles&quot;:&quot;6 cycles&quot;,&quot;end_date&quot;:&quot;2022-06&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;白紫+贝伐&quot;,&quot;start_date&quot;:&quot;2021-05&quot;},{&quot;cycles&quot;:&quot;5 cycles&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;多柔比星&quot;,&quot;start_date&quot;:&quot;2022-07&quot;},{&quot;cycles&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2024-09&quot;,&quot;intent&quot;:&quot;Salvage&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;口服安罗+尼拉&quot;,&quot;start_date&quot;:&quot;2023-01&quot;},{&quot;cycles&quot;:&quot;3 cycles&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Palliative&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;多柔比星+奈达铂&quot;,&quot;start_date&quot;:&quot;2024-09&quot;},{&quot;cycles&quot;:&quot;1&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;intent&quot;:&quot;Palliative&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;联合免疫治疗&quot;,&quot;start_date&quot;:&quot;Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Yes&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;2022-06&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;贝伐维持&quot;],&quot;start_date&quot;:&quot;Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;No&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2019-08&quot;,&quot;evidence&quot;:&quot;CA125 ~110 in 2019.10&quot;,&quot;evidence_type&quot;:&quot;Biochemical&quot;,&quot;first_relapse_date&quot;:&quot;2019-10&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2019-03-26&quot;,&quot;status&quot;:&quot;Unknown&quot;},{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;CT 2025-04-09: ovarian cancer multiple metastases&quot;,&quot;evidence_type&quot;:&quot;Radiologic&quot;,&quot;first_relapse_date&quot;:&quot;2025-04-09&quot;,&quot;line&quot;:&quot;Unknown&quot;,&quot;start_date&quot;:&quot;2024-09&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;Yes&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;2019-10&quot;,&quot;evidence&quot;:&quot;CA125 ~110 in 2019.10&quot;,&quot;type&quot;:&quot;Biochemical&quot;},&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Surgery at outside hospital; postoperative hyperthermic perfusion&quot;},&quot;VISIT_DATE&quot;:&quot;2025-06-27&quot;,&quot;first_relapse_date&quot;:&quot;2019-10&quot;,&quot;last_platinum_end_date&quot;:&quot;Unknown&quot;},&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;CA125&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2019-10&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;≈110&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;651.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;HE4&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;1210.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;pmol/L&quot;},{&quot;analyte&quot;:&quot;CA15-3&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;156.00&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;CA19-9&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;23.40&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/ml&quot;},{&quot;analyte&quot;:&quot;AFP&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;1.04&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;CEA&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;1.13&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;ng/ml&quot;},{&quot;analyte&quot;:&quot;ALP&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↑&quot;,&quot;value&quot;:&quot;143.6&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;U/L&quot;},{&quot;analyte&quot;:&quot;ALB&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;39.5&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/l&quot;},{&quot;analyte&quot;:&quot;Hb&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;67&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;g/l&quot;},{&quot;analyte&quot;:&quot;RBC&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;↓&quot;,&quot;value&quot;:&quot;2.41&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;*10^12/L&quot;},{&quot;analyte&quot;:&quot;WBC&quot;,&quot;history&quot;:[],&quot;latest&quot;:{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;flag&quot;:&quot;Unknown&quot;,&quot;value&quot;:&quot;7.8&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;*10^9/L&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;description&quot;:&quot;Initial surgery at outside hospital&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;description&quot;:&quot;Start adjuvant chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2019-10&quot;,&quot;description&quot;:&quot;Biochemical relapse with CA125 elevation&quot;,&quot;type&quot;:&quot;Relapse&quot;},{&quot;date&quot;:&quot;2025-04-09&quot;,&quot;description&quot;:&quot;CT showed multiple metastases&quot;,&quot;type&quot;:&quot;Imaging&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Unknown&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;Unknown&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[]},&quot;monitoring_points&quot;:[],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;多西+顺铂&quot;,&quot;多西+卡铂&quot;,&quot;多柔比星脂质体&quot;,&quot;白紫+贝伐&quot;,&quot;多柔比星&quot;,&quot;口服安罗+尼拉&quot;,&quot;多柔比星+奈达铂&quot;,&quot;联合免疫治疗&quot;,&quot;贝伐维持&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Ovary&quot;,&quot;Multiple metastases&quot;],&quot;date&quot;:&quot;2025-04-09&quot;,&quot;findings&quot;:[&quot;Ovarian cancer with multiple metastases&quot;],&quot;impression&quot;:&quot;Ovarian cancer with multiple metastases&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Unknown&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2019-03-26&quot;,&quot;description&quot;:&quot;Surgery at outside hospital; postoperative hyperthermic perfusion&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;&quot;},{&quot;date&quot;:&quot;2019-08&quot;,&quot;description&quot;:&quot;Completed adjuvant chemotherapy; PR&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;PR&quot;,&quot;regimen_or_test&quot;:&quot;多西+卡铂&quot;},{&quot;date&quot;:&quot;2019-10&quot;,&quot;description&quot;:&quot;CA125 increased to ~110&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;≈110 U/ml&quot;,&quot;regimen_or_test&quot;:&quot;CA125&quot;},{&quot;date&quot;:&quot;2019-11&quot;,&quot;description&quot;:&quot;Salvage chemotherapy with 多柔比星脂质体, stopped due to pandemic&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;3 cycles, stopped&quot;,&quot;regimen_or_test&quot;:&quot;多柔比星脂质体&quot;},{&quot;date&quot;:&quot;2021-05&quot;,&quot;description&quot;:&quot;Tumor recurrence treated with 白紫+贝伐&quot;,&quot;event_type&quot;:&quot;Relapse&quot;,&quot;key_result&quot;:&quot;6 cycles; bevacizumab maintenance&quot;,&quot;regimen_or_test&quot;:&quot;白紫+贝伐&quot;},{&quot;date&quot;:&quot;2022-06&quot;,&quot;description&quot;:&quot;Bevacizumab maintenance until 2022.06&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;贝伐维持&quot;},{&quot;date&quot;:&quot;2022-07&quot;,&quot;description&quot;:&quot;多柔比星 monotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;5 cycles&quot;,&quot;regimen_or_test&quot;:&quot;多柔比星&quot;},{&quot;date&quot;:&quot;2023-01&quot;,&quot;description&quot;:&quot;Oral therapy started&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;口服安罗+尼拉&quot;},{&quot;date&quot;:&quot;2024-09&quot;,&quot;description&quot;:&quot;Surgery with intestinal stoma for bowel obstruction; stopped oral therapy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;&quot;,&quot;regimen_or_test&quot;:&quot;intestinal stoma&quot;},{&quot;date&quot;:&quot;2024-09&quot;,&quot;description&quot;:&quot;Chemotherapy 多柔比星+奈达铂&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;3 cycles&quot;,&quot;regimen_or_test&quot;:&quot;多柔比星+奈达铂&quot;},{&quot;date&quot;:&quot;Unknown&quot;,&quot;description&quot;:&quot;联合免疫治疗 once, achieved SD&quot;,&quot;event_type&quot;:&quot;Immunotherapy&quot;,&quot;key_result&quot;:&quot;SD&quot;,&quot;regimen_or_test&quot;:&quot;联合免疫治疗&quot;},{&quot;date&quot;:&quot;2025-04-09&quot;,&quot;description&quot;:&quot;External CT showed ovarian cancer multiple metastases&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;multiple metastases&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2025-06-24&quot;,&quot;description&quot;:&quot;Biochemistry and CBC abnormalities&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;ALP 143.6↑; ALB 39.5↓; HGB 67 g/l↓; RBC 2.41↓&quot;,&quot;regimen_or_test&quot;:&quot;Biochemistry/CBC&quot;},{&quot;date&quot;:&quot;2025-06-25&quot;,&quot;description&quot;:&quot;Tumor markers elevated&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;CA125 651.00↑; HE4 1210.00↑; CA15-3 156.00↑; CA19-9 23.40; ROMA 99.50%/98.26%&quot;,&quot;regimen_or_test&quot;:&quot;CA125/HE4/CA15-3/CA19-9/ROMA&quot;}]}}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Expert Debate (Round × Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before proposing any further systemic therapy, please first stabilize anemia (including transfusion decision) and document ECOG, symptom burden, and goals of care; with this heavy pretreatment, we must be explicit whether additional drugs are realistically palliative versus shifting to best supportive care.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Please provide the full 2025-04-09 CT report and any prior comparative imaging to clarify current disease burden, complications, and tempo, as this is critical for deciding whether further systemic therapy is appropriate.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>We need the original ovarian pathology report including histologic subtype, grade, and any prior biomarker testing to inform remaining systemic options versus supportive care only.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>At this stage, do you see any indication for further functional imaging, or would it only add burden without changing management, given heavy pretreatment and anemia?</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>Before deciding on any further systemic therapy versus best supportive care, we urgently need ECOG status, symptom burden, anemia work-up/transfusion history, and the full 2025-04-09 CT report including trends.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>radiologist</td><td>We need the detailed 2025-04-09 CT report and comparison with prior imaging, highlighting disease extent, complications (e.g., bowel obstruction, hydronephrosis), and any rapid progression.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>pathologist</td><td>Please confirm histologic subtype/grade for this ovarian cancer and whether any prior molecular testing (BRCA/HRD, MSI, HER2, others) was done and can be reported.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>oncologist</td><td>Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>oncologist</td><td>No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient.</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 2</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before proposing further systemic therapy, please address and document anemia management (including transfusion decision), ECOG, symptom burden, nutrition, and explicit goals-of-care, as these are critical for safely deciding between additional treatment and best supportive care.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>pathologist</td><td>Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown.</td></tr><tr><td class='mono'>Round 2</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Heavily pretreated metastatic ovarian cancer with rising markers and anemia; current systemic regimen and performance status are unknown/need update.  \n- Prior extensive platinum, liposomal/standard anthracycline, anti-angiogenic, PARP, and immunotherapy exposure suggests limited further cytotoxic benefit; clarify platinum sensitivity.  \n- Immediate priority: correct severe anemia (Hgb 67 g/L) and assess symptoms, nutrition, renal/hepatic function, ECOG.  \n- Obtain histology subtype, BRCA1/2 and HRD status, and complete 2025 imaging reports to guide further systemic vs best supportive care.  \n- Discuss goals of care with patient/family now, aligning intensity of future treatment with prognosis and quality-of-life priorities.&quot;,
  &quot;oncologist&quot;: &quot;- Heavily pretreated metastatic ovarian cancer with progression after multiple cytotoxic, anti-angiogenic, oral targeted, and immunotherapy regimens; palliative intent.  \n\n- Current disease progression: multiple metastases on CT 2025-04-09 with markedly rising CA125/HE4/CA15-3 [@20250625|13601595].  \n\n- Profound anemia (Hb 67 g/L) with preserved liver enzymes and creatinine; requires cause assessment and correction before further systemic therapy [@20250624|14501112][@20250624|14000385].  \n\n- No germline/somatic mutations, MSI, TMB, or PD-L1 data available; comprehensive molecular profiling status and reports need updating.  \n\n- Missing details: exact histology/grade, staging, performance status, organ function (full labs), prior regimen toxicities, prior response durations, and sites/symptoms.&quot;,
  &quot;radiologist&quot;: &quot;- CT shows ovarian malignancy with multiple metastatic sites; precise organs, sizes, and counts not specified and need updated imaging report. [@IMAGING_STUDIES|2025-04-09]\n\n- Overall metastatic burden and distribution trend versus any earlier baseline are unknown; prior comparison imaging, if available, needs review. [@IMAGING_TRENDS|2025-04-09]\n\n- No documentation of complications such as obstruction, ascites, or organ compromise; targeted CT/PET report needed to assess. [unknown/needs update]\n\n- Lesion measurability for response assessment (target vs non-target lesions) cannot be determined; require full radiology report with measurements. [unknown/needs update]&quot;,
  &quot;pathologist&quot;: &quot;- Markedly elevated CA125 and HE4 with high ROMA suggest strong suspicion for epithelial ovarian malignancy; histologic confirmation absent. [@MOLECULAR|unknown]  \n- Normal AFP, CEA, CA19-9, CA15-3 reduce support for primary germ cell or GI-type tumor markers. [@MOLECULAR|unknown]  \n- No tissue diagnosis, histologic type, or grade available; surgical pathology or biopsy report urgently needed. [@PATHOLOGY_REPORTS|unknown]  \n- HER2, MSI, PD-L1 CPS, and TMB all unknown; these biomarkers require dedicated testing if clinically indicated. [@MOLECULAR|unknown]  \n- Germline and somatic mutation panels show no reported variants; confirm panel type, genes covered, and report date. [@MOLECULAR|unknown]&quot;,
  &quot;nuclear&quot;: &quot;- No PET/CT report available; current staging metabolic extent is unknown/needs update [@PET_CT|unknown].  \n- Prior imaging shows ovarian cancer with multiple metastases, but metabolic activity pattern is unknown/needs update [@IMAGING_CONTEXT|2025-04-09].  \n- Cannot assess PET impact on upstaging/downstaging or recurrence suspicion without a current PET report; acquisition status unknown/needs update.  \n- Need PET/CT date, acquisition protocol, FDG-avid lesion distribution, and SUV metrics to refine metastatic burden assessment.  \n- Request upload/verification of latest PET/CT report to determine any change in staging or recurrence suspicion.&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Prioritize stabilization: evaluate anemia cause, consider transfusion, repeat CBC/biochem, document ECOG, symptoms, nutrition, comorbidities [@20250624|14501112; @20250624|14000385].  \n- Retrieve and review original pathology, including histologic subtype, grade, and any prior molecular testing; order germline/somatic profiling if absent.  \n- Obtain full 2025-04-09 CT report and any subsequent imaging; assess disease distribution, complications, and trend vs prior (currently unknown).  \n- Reconstruct detailed systemic treatment history (agents, dates, responses, toxicities, PFI) to clarify platinum status and realistic systemic options.  \n- After stabilization and data completion, hold MDT plus goals-of-care meeting to weigh further systemic therapy versus best supportive/palliative care.&quot;,
    &quot;oncologist&quot;: &quot;- Correct severe anemia urgently (transfusion and work-up), then document ECOG, symptom burden, nutrition, and comorbidities before any new regimen [@20250624|14501112].  \n\n- Obtain and review full 2025-04-09 CT report (organs involved, complications, comparison) and any PET/CT to reassess disease burden (currently missing).  \n\n- Retrieve original pathology to confirm epithelial subtype/grade and review any prior molecular testing; if absent, consider comprehensive profiling (currently unknown).  \n\n- Reconstruct detailed prior systemic treatment history, including responses and toxicities, to clarify platinum sensitivity and realistic benefit of further therapy (missing).  \n\n- After stabilization and data completion, re-discuss at MDT and with patient/family to choose between limited further systemic therapy versus best supportive care.&quot;,
    &quot;radiologist&quot;: &quot;- Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison) remains missing; must be retrieved/uploaded before MDT. [@IMAGING_STUDIES|2025-04-09]\n\n- PET/CT since 2025-04-09 is unknown; confirm if performed and obtain report/images to define metabolic burden and complications. [unknown/needs update]\n\n- Without full imaging, current disease extent, obstruction risk, or other complications cannot be adequately assessed for further systemic vs supportive care decisions. [@IMAGING_STUDIES|2025-04-09]\n\n- Once prior imaging is available, perform structured radiologic staging and measurability assessment to support objective response evaluation if therapy pursued. [unknown/needs update]&quot;,
    &quot;pathologist&quot;: &quot;- Retrieve and review original ovarian cancer pathology: histologic subtype, grade, stage, and biomarker profile are completely unknown/needs update.  \n- Obtain details of any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2); currently unknown/needs update.  \n- Confirm disease origin as ovarian versus alternative primary once pathology is available; present clarification at next MDT.  \n- Once tissue and molecular data are complete, update pathology summary focusing on features relevant to further systemic options (no regimens suggested).  \n- Ensure all key pathology and molecular reports are uploaded and correctly dated to avoid future discrepancies in MDT decisions.&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT available; current metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \n- Full CT 2025-04-09 report is still missing; without it, we cannot correlate anatomic and potential metabolic burden [@IMAGING_CONTEXT|2025-04-09].  \n- If PET/CT is performed, key goals: clarify extra-abdominal spread, occult nodal disease, and complications not fully characterized on CT.  \n- PET would meaningfully change staging only if it reveals unsuspected distant metastases or non-malignant explanations for some CT lesions.  \n- For suspected recurrence/progression, PET could reclassify equivocal CT findings, influencing decisions about local versus purely systemic/supportive approaches.&quot;
  },
  &quot;Round 2&quot;: {
    &quot;chair&quot;: &quot;- Correct severe anemia urgently, including transfusion consideration; reassess ECOG, symptoms, nutrition, and organ function afterward [@20250624|14501112; @20250624|14000385].  \n- Conduct structured goals-of-care discussion post-stabilization to clarify preferences regarding further systemic therapy versus best supportive care.  \n- Retrieve and review full primary pathology and any prior molecular testing; if absent, consider feasibility and value of new profiling.  \n- Obtain full 2025-04-09 CT report and any PET/CT to define metastatic burden, complications, and need for local palliative interventions.  \n- After data completion, re-convene MDT to weigh modest systemic options against toxicity, prioritizing symptom-led palliative/supportive care if performance status poor.&quot;,
    &quot;oncologist&quot;: &quot;- Urgently correct severe anemia and complete anemia work-up; reassess ECOG, symptoms, nutrition, comorbidities, and preferences before new therapy [@20250624|14501112].  \n\n- Obtain full CT 2025-04-09 report and confirm any PET/CT to define metastatic burden, complications, and trends (currently missing).  \n\n- Retrieve original pathology and any prior molecular testing; if absent, consider profiling to clarify histology and actionable biomarkers (all currently unknown).  \n\n- Reconstruct detailed prior systemic treatment history and responses to better infer platinum sensitivity and realistic benefit of further systemic therapy (missing).  \n\n- After stabilization and data completion, re-discuss at MDT and with patient/family to decide between limited further therapy versus best supportive care.&quot;,
    &quot;radiologist&quot;: &quot;- CT confirms metastatic ovarian cancer; exact metastatic sites, lesion sizes, and complications remain unspecified and require full report retrieval. [@IMAGING_STUDIES|2025-04-09]\n\n- Comparison of 2025-04-09 CT with any earlier imaging is undocumented; prior studies must be located to assess progression trend. [@IMAGING_TRENDS|2025-04-09]\n\n- Presence or absence of obstructive complications (bowel, ureteric, biliary) on CT is unknown; detailed abdominopelvic review is needed. [unknown/needs update]\n\n- PET/CT history and findings are undocumented; confirm if performed and upload reports/images to better define metabolic disease extent. [unknown/needs update]\n\n- Once complete imaging is available, provide structured staging, RECIST measurability, and description of any life-threatening complications for MDT planning. [unknown/needs update]&quot;,
    &quot;pathologist&quot;: &quot;- Original ovarian tumor histology, grade, staging, and IHC remain unknown/needs update; retrieve and upload full primary pathology report.  \n- Clarify whether any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2) was done; currently unknown/needs update.  \n- Once pathology is available, confirm epithelial ovarian origin versus alternative primary and summarize key prognostic/pathologic features for MDT.  \n- If sufficient archived tissue exists, consider feasibility of additional biomarker testing, but only after full prior pathology/molecular review.  \n- Ensure all pathology and molecular documents are correctly labeled and dated to avoid misinterpretation in future MDT discussions.&quot;,
    &quot;nuclear&quot;: &quot;- No PET/CT or nuclear report is available; metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \n- CT shows metastatic ovarian cancer, but organ involvement, lesion size, and complications remain insufficiently characterized/needs update [@IMAGING_CONTEXT|2025-04-09].  \n- Clarifying whether any prior PET/CT exists is critical to better define current metastatic spread and potential extra-abdominal disease.  \n- Once available, PET/CT could help distinguish active disease from treatment-related changes or benign findings on CT, refining staging.  \n- In this heavily pretreated, palliative setting, PET’s main role would be clarifying true progression versus equivocal CT findings, not surveillance.&quot;
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Selected Clinical Context (JSON)</summary>
    <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20250624|14000385&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;白蛋白 39.5 g/l (ALB)\n谷草同工酶 6.9 U/L (ASTM)\n总蛋白 70.5 g/l (TP)\n球蛋白 31.0 g/l (GELO)\n游离脂肪酸 0.30 mmol/L (NEFA)\n尿酸 362 umol/l (UA)\n天冬氨酸氨基转移酶 18.0 U/L (AST)\n直接胆红素 1.7 umol/l (DBIL)\nγ-谷氨酰基转移酶 35 U/L (GGT)\n尿素 11.22 mmol/l (UREA)\n白球比例 1.27 nan (A/G)\n肌酐 93 umol/l (CRE)\n乳酸脱氢酶 209 U/L (LDH)\n丙氨酸氨基转移酶 8.6 U/l (ALT)\n碱性磷酸酶 143.6 U/L (ALP)\n前白蛋白 172 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n谷氨酸脱氢酶 3.8 U/L (GLDH)\n总胆红素 3.6 umol/l (TBIL)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250624|14501112&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;红细胞比积 22.3 % (HCT)\n平均红细胞血红蛋白量 27.8 pg (MCH)\n平均PLT容积 8.4 fl (MPV)\n中性淋巴比值 4.14 nan (NL)\n自动审核标志 ACCEPT nan (VFLAG)\n白细胞计数 7.8 *10^9/L (WBC)\n血红蛋白量 67 g/l (HGB)\n平均红细胞体积 92.5 fl (MCV)\n嗜酸性细胞数 0.09 *10^9/L (EOS#)\n嗜酸性细胞% 1.20 % (EOS)\n淋巴细胞% 18.2 % (LYM)\n单核细胞% 6.2 % (MID)\nPLT分布宽度 7 % (PDW)\n嗜碱性细胞数 0.02 *10^9/L (BASO#)\n嗜碱性细胞% 0.30 % (BASO)\n中性粒细胞% 74.1 % (GRAN)\n淋巴细胞数 1.4 *10^9/L (LYM#)\n中性粒细胞数 5.8 *10^9/L (GRAN#)\n红细胞计数 2.41 *10^12/L (RBC)\n血小板计数 198 *10^9/L (PLT)\nRBC分布宽度-CV 16.1 % (RDWCV)\n单核细胞数 0.5 *10^9/L (MID#)\n平均红细胞血红蛋白浓度 300.0 g/l (MCHC)\n血小板压积 0.17 % (PCT)\nRBC分布宽度-SD 56 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250625|13601595&quot;,
        &quot;date&quot;: &quot;2025-06-25T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;卵巢恶性肿瘤风险值. 98.26 %(绝经后) (ROMA.)\n糖链抗原125 651.00 U/ml (CA125)\n糖链抗原19-9 23.40 U/ml (CA19-9)\n人附睾蛋白4 1210.00 pmol/L (HE4)\n糖链抗原15-3 156.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 99.50 %(绝经前) (ROMA)\n癌胚抗原 1.13 ng/ml (CEA)\n甲胎蛋白 1.04 ng/ml (AFP)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20250624|14000385&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;白蛋白 39.5 g/l (ALB)\n谷草同工酶 6.9 U/L (ASTM)\n总蛋白 70.5 g/l (TP)\n球蛋白 31.0 g/l (GELO)\n游离脂肪酸 0.30 mmol/L (NEFA)\n尿酸 362 umol/l (UA)\n天冬氨酸氨基转移酶 18.0 U/L (AST)\n直接胆红素 1.7 umol/l (DBIL)\nγ-谷氨酰基转移酶 35 U/L (GGT)\n尿素 11.22 mmol/l (UREA)\n白球比例 1.27 nan (A/G)\n肌酐 93 umol/l (CRE)\n乳酸脱氢酶 209 U/L (LDH)\n丙氨酸氨基转移酶 8.6 U/l (ALT)\n碱性磷酸酶 143.6 U/L (ALP)\n前白蛋白 172 mg/L (PA)\n间接胆红素 1.9 umol/L (IBIL)\n谷氨酸脱氢酶 3.8 U/L (GLDH)\n总胆红素 3.6 umol/l (TBIL)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250624|14501112&quot;,
        &quot;date&quot;: &quot;2025-06-24T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;红细胞比积 22.3 % (HCT)\n平均红细胞血红蛋白量 27.8 pg (MCH)\n平均PLT容积 8.4 fl (MPV)\n中性淋巴比值 4.14 nan (NL)\n自动审核标志 ACCEPT nan (VFLAG)\n白细胞计数 7.8 *10^9/L (WBC)\n血红蛋白量 67 g/l (HGB)\n平均红细胞体积 92.5 fl (MCV)\n嗜酸性细胞数 0.09 *10^9/L (EOS#)\n嗜酸性细胞% 1.20 % (EOS)\n淋巴细胞% 18.2 % (LYM)\n单核细胞% 6.2 % (MID)\nPLT分布宽度 7 % (PDW)\n嗜碱性细胞数 0.02 *10^9/L (BASO#)\n嗜碱性细胞% 0.30 % (BASO)\n中性粒细胞% 74.1 % (GRAN)\n淋巴细胞数 1.4 *10^9/L (LYM#)\n中性粒细胞数 5.8 *10^9/L (GRAN#)\n红细胞计数 2.41 *10^12/L (RBC)\n血小板计数 198 *10^9/L (PLT)\nRBC分布宽度-CV 16.1 % (RDWCV)\n单核细胞数 0.5 *10^9/L (MID#)\n平均红细胞血红蛋白浓度 300.0 g/l (MCHC)\n血小板压积 0.17 % (PCT)\nRBC分布宽度-SD 56 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20250625|13601595&quot;,
        &quot;date&quot;: &quot;2025-06-25T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;卵巢恶性肿瘤风险值. 98.26 %(绝经后) (ROMA.)\n糖链抗原125 651.00 U/ml (CA125)\n糖链抗原19-9 23.40 U/ml (CA19-9)\n人附睾蛋白4 1210.00 pmol/L (HE4)\n糖链抗原15-3 156.00 U/ml (CA15-3)\n卵巢恶性肿瘤风险值 99.50 %(绝经前) (ROMA)\n癌胚抗原 1.13 ng/ml (CEA)\n甲胎蛋白 1.04 ng/ml (AFP)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  }
}</pre>
  </details>

  <details class="mt">
    <summary>Global Guideline RAG</summary>
    <h3>RAG Query</h3>
    <pre>Heavily pretreated recurrent ovarian cancer, platinum status unclear, with multiple metastases on CT; no BRCA/HRD/MSI/PD-L1 data; significant anemia (Hgb 67), low albumin, rising CA125/HE4—guidance on systemic options and supportive care?</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre>(RAG: no evidence found)</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[]</pre>
    <h3>Digest (<=8 bullets)</h3>
    <pre>- No directly relevant guideline or trial-based evidence was retrieved for this query (RAG: no evidence found).</pre>
  </details>

  <details class='mt' open><summary>Pipeline Flow (Mermaid)</summary><pre class='mermaid'>flowchart TD
  A[Load Case + Fingerprint] --&gt; B[Load Reports]
  B --&gt; C[Report Selection per Role]
  C --&gt; D[Global Guideline RAG]
  D --&gt; E[Init Specialist Agents]
  E --&gt; F[MDT Discussion Engine]
  F --&gt; G[Trial Matching]
  G --&gt; H[Final Chair Output]
  H --&gt; I[Save Logs]
</pre></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-17T20:08:58.975306&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2025-06-27 15:54:59.567000&quot;,
      &quot;meta_info&quot;: &quot;362201196403235065&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:08:58.975549&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;d9b11a1ab0f2&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:08:59.231136&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 16,
      &quot;img_n&quot;: 2,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 0,
      &quot;cutoff_dt&quot;: &quot;2025-06-28 15:54:59&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:09:09.632085&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20250624|14000385|2025-06-24&quot;,
          &quot;20250624|14501112|2025-06-24&quot;,
          &quot;20250625|13601595|2025-06-25&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20250624|14000385|2025-06-24&quot;,
          &quot;20250624|14501112|2025-06-24&quot;,
          &quot;20250625|13601595|2025-06-25&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:09:30.216977&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;Heavily pretreated recurrent ovarian cancer, platinum status unclear, with multiple metastases on CT; no BRCA/HRD/MSI/PD-L1 data; significant anemia (Hgb 67), low albumin, rising CA125/HE4—guidance on systemic options and supportive care?&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:09:30.216981&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;topk&quot;: 5,
      &quot;n&quot;: 0
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:09:32.499992&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:12:13.807415&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2924
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:12:13.808337&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-17T20:12:16.934295&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 1141
    }
  }
]</pre>
  </details>

</body>
</html>
